- Home
- GGB vs BPMC Comparison
GGB vs BPMC Comparison
Compare GGB & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- BPMC
- Stock Information
- Founded
- GGB 1901
- BPMC 2008
- Country
- GGB Brazil
- BPMC United States
- Employees
- GGB N/A
- BPMC N/A
- Industry
- GGB Steel/Iron Ore
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- BPMC Health Care
- Exchange
- GGB Nasdaq
- BPMC Nasdaq
- Market Cap
- GGB 5.5B
- BPMC 5.8B
- IPO Year
- GGB 1999
- BPMC 2015
- Fundamental
- Price
- GGB $2.67
- BPMC $87.66
- Analyst Decision
- GGB Buy
- BPMC Buy
- Analyst Count
- GGB 2
- BPMC 22
- Target Price
- GGB $5.00
- BPMC $124.48
- AVG Volume (30 Days)
- GGB 11.4M
- BPMC 1.1M
- Earning Date
- GGB 04-28-2025
- BPMC 05-01-2025
- Dividend Yield
- GGB 5.28%
- BPMC N/A
- EPS Growth
- GGB N/A
- BPMC N/A
- EPS
- GGB 0.35
- BPMC N/A
- Revenue
- GGB $10,837,144,685.00
- BPMC $508,824,000.00
- Revenue This Year
- GGB $8.01
- BPMC $44.85
- Revenue Next Year
- GGB $4.95
- BPMC $32.06
- P/E Ratio
- GGB $7.35
- BPMC N/A
- Revenue Growth
- GGB N/A
- BPMC 104.04
- 52 Week Low
- GGB $2.27
- BPMC $73.04
- 52 Week High
- GGB $4.04
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- GGB 49.73
- BPMC 53.93
- Support Level
- GGB $2.49
- BPMC $83.27
- Resistance Level
- GGB $2.69
- BPMC $86.85
- Average True Range (ATR)
- GGB 0.12
- BPMC 4.35
- MACD
- GGB 0.02
- BPMC 0.91
- Stochastic Oscillator
- GGB 94.05
- BPMC 98.98
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.